03:10 PM EDT, 10/04/2024 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Friday it will present the three-year safety and efficacy results from its HOPE-2 open-label extension study with its lead asset deramiocel for treating Duchenne muscular dystrophy.

The data will highlight the long-term, multi-modal benefits of deramiocel in a late-breaking poster presentation at the World Muscle Society's annual congress in Prague next week, the company said.

Shares of the company were up more than 27% in recent trading.

Price: 21.71, Change: +4.64, Percent Change: +27.19